134 related articles for article (PubMed ID: 35582228)
1. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.
Lee KJ; Wright G; Bryant H; Wiggins LA; Schuler M; Gassman NR
Cancer Drug Resist; 2020; 3(4):980-991. PubMed ID: 35582228
[No Abstract] [Full Text] [Related]
2. A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.
Gatti-Mays ME; Karzai FH; Soltani SN; Zimmer A; Green JE; Lee MJ; Trepel JB; Yuno A; Lipkowitz S; Nair J; McCoy A; Lee JM
Oncologist; 2020 Dec; 25(12):1013-e1824. PubMed ID: 32510664
[TBL] [Abstract][Full Text] [Related]
3. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor.
Hong DS; Moore KN; Bendell JC; Karp DD; Wang JS; Ulahannan SV; Jones S; Wu W; Donoho GP; Ding Y; Capen A; Wang X; Bence Lin A; Patel MR
Clin Cancer Res; 2021 Apr; 27(7):1864-1874. PubMed ID: 33495309
[TBL] [Abstract][Full Text] [Related]
5. Combating CHK1 resistance in triple negative breast cancer: EGFR inhibition as potential combinational therapy.
Stefanski CD; Prosperi JR
Cancer Drug Resist; 2022; 5(1):229-232. PubMed ID: 35582533
[TBL] [Abstract][Full Text] [Related]
6. A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Blosser WD; Dempsey JA; McNulty AM; Rao X; Ebert PJ; Lowery CD; Iversen PW; Webster YW; Donoho GP; Gong X; Merzoug FF; Buchanan S; Boehnke K; Yu C; You XT; Beckmann RP; Wu W; McNeely SC; Lin AB; Martinez R
Oncotarget; 2020 Jan; 11(3):216-236. PubMed ID: 32076484
[TBL] [Abstract][Full Text] [Related]
7. The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.
Lowery CD; VanWye AB; Dowless M; Blosser W; Falcon BL; Stewart J; Stephens J; Beckmann RP; Bence Lin A; Stancato LF
Clin Cancer Res; 2017 Aug; 23(15):4354-4363. PubMed ID: 28270495
[No Abstract] [Full Text] [Related]
8. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
Sohn J; Liu S; Parinyanitikul N; Lee J; Hortobagyi GN; Mills GB; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2014; 5(9):745-53. PubMed ID: 25368674
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
10. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
[TBL] [Abstract][Full Text] [Related]
11. Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Lowery CD; Dowless M; Renschler M; Blosser W; VanWye AB; Stephens JR; Iversen PW; Lin AB; Beckmann RP; Krytska K; Cole KA; Maris JM; Hawkins DS; Rubin BP; Kurmasheva RT; Houghton PJ; Gorlick R; Kolb EA; Kang MH; Reynolds CP; Erickson SW; Teicher BA; Smith MA; Stancato LF
Clin Cancer Res; 2019 Apr; 25(7):2278-2289. PubMed ID: 30563935
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
Kim EM; Mueller K; Gartner E; Boerner J
J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
[TBL] [Abstract][Full Text] [Related]
13. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
14. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
[TBL] [Abstract][Full Text] [Related]
15. Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up-regulation.
Zhao X; Kim IK; Kallakury B; Chahine JJ; Iwama E; Pierobon M; Petricoin E; McCutcheon JN; Zhang YW; Umemura S; Chen V; Wang C; Giaccone G
Mol Oncol; 2021 Apr; 15(4):1130-1145. PubMed ID: 33320980
[TBL] [Abstract][Full Text] [Related]
16. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
17. Metalloprotease-dependent activation of EGFR modulates CD44
Wise R; Zolkiewska A
Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
[TBL] [Abstract][Full Text] [Related]
18. IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells.
Itoh T; Hatano R; Horimoto Y; Yamada T; Song D; Otsuka H; Shirakawa Y; Mastuoka S; Iwao N; Aune TM; Dang NH; Kaneko Y; Okumura K; Morimoto C; Ohnuma K
Cell Death Dis; 2021 May; 12(6):520. PubMed ID: 34021125
[TBL] [Abstract][Full Text] [Related]
19. IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Merrouche Y; Fabre J; Cure H; Garbar C; Fuselier C; Bastid J; Antonicelli F; Al-Daccak R; Bensussan A; Giustiniani J
Oncotarget; 2016 Aug; 7(33):53350-53361. PubMed ID: 27462789
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERĪ± expression and proliferation in luminal primary and metastatic breast cancer cells.
Pescatori S; Leone S; Cipolletti M; Bartoloni S; di Masi A; Acconcia F
J Exp Clin Cancer Res; 2022 Apr; 41(1):141. PubMed ID: 35418303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
